A unique approach
KaNDy Therapeutics was spun out from NeRRe Therapeutics in 2017 at which time all data and intellectual property associated with NT-814 was transferred to KaNDy Therapeutics.
NT-814 is a unique, first-in-class dual mechanism NK-1,3 antagonist therapy dosed orally once daily. It has the potential to be a true breakthrough non-hormonal alternative to hormone replacement therapy (HRT). Following a successful Phase 2a proof of concept study , NT-814 completed a Phase 2b study, SWITCH-1, with data reported in January 2020. The study demonstrated NT-814’s potential to rapidly and profoundly reduce key symptoms of the menopause. SWITCH-1 found that NT-814 significantly reduced the frequency of hot flashes, which was associated with improvements in quality of life, mood and sleep.
Menopausal vasomotor symptoms (hot flashes/flushes) affect up to 75% of women going through the menopausal transition. Symptoms last for 1–2 years after menopause in most women but may continue for up to 10 years or longer in others. Post-menopausal symptoms are experienced daily by millions of women globally. Approximately 20% of women will suffer from debilitating symptoms, multiple times a day. Hot flashes are the primary reason women seek medical help during the menopause. Not only do they disturb women at work and interrupt daily activities, but they also have a detrimental effect on sleep. These symptoms, while not life-threatening or life-limiting, are debilitating for those affected and result in significant incremental healthcare and economic costs.
KaNDy Therapeutics is led by an experienced management team and backed by internationally recognised life sciences investors: Advent Life Sciences, Fountain Healthcare Partners, Forbion Capital Partners, OrbiMed and Longitude Capital.
KaNDy Therapeutics is based at the state-of-the-art Stevenage Bioscience Catalyst, the UK’s first open innovation bioscience campus.